美托洛尔治疗慢性心力衰竭的临床疗效及安全性评价

目的探讨美托洛尔治疗慢性心力衰竭的疗效和安全性。方法85例慢性心力衰竭患者随机分为美托洛尔组（43例）和对照组（42例）。对照组采用心力衰竭的常规治疗方案,治疗组在心力衰竭常规治疗方案基础上加用美托洛尔,治疗1年。结果美托洛尔组心功能及超声心动图情况改善、左室舒张末径减小,左室射血分数明显增加,与对照组比较差异有统计学意义（P〈0.05）,美托洛尔组有6例出现头昏、乏力、心动过缓,经调整剂量后未影响继续用药。美托洛尔组治疗后肝、肾功能、电解质、血糖、血脂、血常规及尿常规均无异常改变。结论美托洛尔治疗慢性心力衰竭安全有效。

Safety evaluation and clinical curative effect of metoprolol on chronic heart failure

Objective To investigate the efficacy and safety of metoprolol in patients with chronic heart failure（CHF）.Methods 85 patients with CHF were divided into metoprolol group（43）and control group（42） randomly,standard therapeutic scheme was used in control group,metoprolol was used in metoprolol group based on standard therapeutic scheme The treatment courses were 1 year in both groups.Results Left ventricular end-diastolic diameter（LVEDD）was reduced and 1eft yen tricular ejection fraction（LVEF）increased in metoprolol group with significant difference comparing with control group（P〈0.05）.The adverse reaction of metoprolol were mostly dizziness asthenia,bradycardia and hypotension,no damage of liver and or kidney function or changes of hemogram,blood-lipid,electrolyte and blood sugar were found. Conclusion Metoprolol is proved be effective and safe in treating CHF.